Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX168 in ANCA-associated renal vasculitis on cyclophosphamide background therapy
ISRCTN53663626Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Aug 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of avacopan in antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN) (4 arms), sponsored by ChemoCentryx. Primary endpoint: Safety of CCX168 in ANCA-associated renal vasculitis. Started Aug 2011; status: completed.
02
Drugs
avacopan
03
Conditions
antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN)
Beyond the preview
Go deeper on ISRCTN53663626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53663626.